Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis

23 Sept 2025

Abstract excerpt

BACKGROUND: The emergence of novel human epidermal growth factor receptor 2 (HER2)-targeting drugs has provided a new therapeutic option for HER2-low triple-negative breast cancer (TNBC) patients who had limited treatment choices previously. However, the biological implications and prognostic significance of HER2-low status in TNBC are still not fully appreciated. METHODS: Utilizing a single-center multi-omics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40991980
DOI: 10.1016/j.breast.2025.104584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisPMID 40991980Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

Multi-Omics and Single-Cell Sequencing Reveal the Genomic Features and Metabolic Heterogeneity of Low Ki-67 Triple-Negative Breast CancerSemantic proximity Read ↗

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.Semantic proximity Read ↗

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.Semantic proximity Read ↗

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Semantic proximity Read ↗

Secondary Transcriptomic Analysis of Triple Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific BiomarkersSemantic proximity Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

The Molecular Landscape and Utility of Multiomic Analyses in Triple Negative Breast Cancer: Further Subtyping and Exploring Novel Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

[Biological characteristics of triple negative breast cancer with low expression of HER2].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.